CLINICAL_TRIALS
trial_result
· 2012-05-15
Clinical Trial Update: Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy [Phase 2]
Summary
Phase 2 trial evaluating Rituximab in patients with refractory or recurrent hairy cell leukemia after cladribine therapy has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Swiss Cancer Institute | Conditions: Leukemia | Phase 2 | Status: COMPLETED